NPR3 and atrial fibrillation: Co-treatment of wild-type mice with angiotensin-II and cANF (a synthetic, selective NPR-C agonist90) reduces AF burden, while improving atrial conduction, attenuating atrial fibrosis, and improving AP properties.77